moneyheap
KRYS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Krystal Biotech, Inc. Common Stock (KRYS) stock moving?
KRYS fell 10.9% on Nov 2, from $332.29 to $295.90, on about 1.2M shares, roughly four times the prior sessions' typical volume. The drop came the same day as Q3 2026 results, which showed net product revenue of $127.3M and a new $400M buyback, but also delayed data for KB803, KB801 and KB407 into 2027. Since then the stock has recovered to $306.50 on Nov 10, while volume has eased back to about 196K shares. Analysts kept Buy or Outperform ratings after trimming targets to $375-$412 (RBC, TD Cowen, Citigroup), and some describe the drop as overblown. Company updates also point to near-term items: KB111 interim data before year-end, a Vyjuvek Italy launch in early 2027, and the KB803 topline shortly after last patient visit in Feb 2027. The Galien nomination and conference participation are minor. The main risks are the pipeline slippage, a 2026 non-GAAP R&D and SG&A guide of $155-165M, and net income of $63.1M, below the $79.4M a year earlier.
News behind the analysis
- Krystal Biotech Announces Participation in Upcoming Investor ConferencesManagement will take part in fireside chats and host investor meetings at three upcoming healthcare conferences.
- Krystal Biotech's Vyjuvek Nominated for 2026 Prix Galien AwardVyjuvek was named a nominee in the 'Best Medical Technology / AI Advances in Human Health' category by the Galien Foundation.
- Krystal Biotech Reports Third Quarter 2026 Financial Results and Announces Share Repurchase ProgramQ3 2026 net product revenue was $127.3M, and a new $400M share repurchase program was announced.
- Krystal Biotech Delays Pipeline Data Releases to 2027Expected data for KB803, KB801 and KB407 were pushed to 2027, and the stock fell on the news.
- Krystal Biotech Analyst Says Stock Weakness 'Overblown'Analysts called the post-earnings drop overblown after a Q3 beat, highlighting a possible buying opportunity despite trial delays.
- Krystal Biotech Says KB801 Eye Trial Enrollment Slower Than Expected; Now Sees Topline Data In 2027Slower KB801 eye trial enrollment moved topline data into 2027.
- RBC Lowers Price Target on Krystal Biotech to $375 From $400, Keeps Outperform RatingRBC cut its price target to $375 from $400 but kept its Outperform rating after Q3 earnings.
- Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412Citigroup kept its Buy rating and lowered its price target to $412 from $416 after Q3 earnings.
- TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380TD Cowen kept its Buy rating and set a $380 price target after Q3 earnings.
About Krystal Biotech, Inc. Common Stock
Krystal Biotech is a Pittsburgh-based biotech company that develops and sells genetic medicines for serious diseases that have few treatment options. What sets it apart is that it is already profitable from one approved product, VYJUVEK, a gene therapy applied to the skin to treat the rare blistering disorder dystrophic epidermolysis bullosa.
How it makes money
Nearly all of its revenue comes from net sales of VYJUVEK, which brought in roughly $127 million in Q3 2026, up from about $116 million in Q1 2026. Gross margins are very high, around 95%. Product sales pay for a pipeline built on the same gene-delivery platform, with programs in cystic fibrosis lung disease, oncology (such as KB707) and other areas. In November 2026 the company also announced a share buyback of about $400 million over two years.
What usually moves KRYS
- VYJUVEK sales growth and uptake in new countries
- Clinical trial readouts for pipeline programs (cystic fibrosis, oncology)
- FDA and other regulatory decisions
- Quarterly earnings compared with analyst expectations
- Competition in treatments for epidermolysis bullosa